^
    Back
    Association details:
    Biomarker:PRMT5 overexpression + MTAP deletion
    Cancer:Mantle Cell Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma

    Published date:
    11/06/2019
    Excerpt:
    We found that PRMT5 is highly expressed in ibrutinib-resistant MCL but not ibrutinib-sensitive MCL (...p = 0.0051), especially in MTAP-deleted MCL specimens. Furthermore, patients with high PRMT5 levels had poor clinical outcomes on ibrutinib treatment.
    DOI:
    https://doi.org/10.1182/blood-2019-125934